title: Assessing the prevalence of opioid misuse, abuse, and addiction in chronic pain.
authors: Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA, USA.
authors: Jane C
authors: JC
authors: Ballantyne
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects*; D016739:Behavior, Addictive / Q000453:epidemiology*; D006801:Humans; D009293:Opioid-Related Disorders / Q000453:epidemiology*; D019966:Substance-Related Disorders / Q000453:epidemiology*
chemical_list: D000701:Analgesics, Opioid
references: Ballantyne JC, LaForge SL. Opioid dependence and addiction in opioid treated pain patients. PAIN 2007;129:235–55.
references: Ballantyne JC, Stannard C. New addiction criteria: diagnostic challenges persist in treating pain with opioids. PAIN 2013;21:1–7.
references: Ballantyne JC, Sullivan MD, Kolodny A. Opioid dependence vs addiction: a distinction without a difference? Arch Intern Med 2012;172:1342–3.
references: Butler S. The IMMPACT factor or IMMPACT strikes again! PAIN 2013;154:2243–4.
references: Hyman S, Malenka R. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001;2:695–703.
references: Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006;29:565–98.
references: Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. PAIN 2010;150:390–400.
references: Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropharm 2001;24:97–129.
references: Kreek MJ, Nielsen DA, Butelman ER, LaForge KS. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005;8:1450–7.
references: Moore N, Pariente A, Begaud B. Why Are Benzodiazepines Not Yet Controlled Substances? JAMA Psychiatry 2015;72:110–1.
references: Nestler EJ. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci 2004;25:210–8.
references: O'Connor AB, Turk DC, Dworkin RH, Katz NP, Colucci R, Haythornthwaite JA, Klein M, O'Brien C, Posner K, Rappaport BA, Reisfield G, Adams EH, Balster RL, Bigelow GE, Burke LB, Comer SD, Cone E, Cowan P, Denisco RA, Farrar JT, Foltin RW, Haddox JD, Hertz S, Jay GW, Junor R, Kopecky EA, Leiderman DB, McDermott MP, Palmer PP, Raja SN, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Smith SM, Sokolowska M, Stauffer JW, Walsh SL, Zacny JP. Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. PAIN 2013;154:2324–34.
references: Robinson T, Berridge K. The neural incentive basis of drug craving: an incentive snsitization theory of addiction. Brain Res Rev 1993;18:247–91.
references: Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. PAIN 2013;154:2287–96.
references: Sullivan M. Clarifying opioid misuse and abuse. PAIN 2013;154:2239–40.
references: Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes D. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. PAIN 2015;156:569–576.